{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:24:01Z","timestamp":1773318241459,"version":"3.50.1"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recent discoveries shed light on molecular mechanisms responsible for classical Hodgkin lymphoma (HL) development and progression, along with features of Hodgkin \u2013 Reed and Sternberg cells (HRS). Here, we summarize current knowledge on characteristic molecular alterations in HL, as well as existing targeted therapies and potential novel treatments for this disease. We discuss the importance of cluster of differentiation molecule 30 (CD30) and the programmed cell death-1 protein (PD-1) and ligands (PD-L1\/2), and other molecules involved in immune modulation in HL. We highlight emerging evidence indicating that the altered function of SWI\/SNF-type chromatin remodeling complexes, PRC2, and other epigenetic modifiers, contribute to variations in chromatin status, which are typical for HL. We postulate that despite of the existence of plentiful molecular data, the understanding of HL development remains incomplete. We therefore propose research directions involving analysis of reverse signaling in the PD-1\/PD-L1 mechanism, chromatin remodeling, and epigenetics-related alterations, in order to identify HL features at the molecular level. Such attempts may lead to the identification of new molecular targets, and thus will likely substantially contribute to the future development of more effective targeted therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1155468","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T04:36:35Z","timestamp":1684125395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["New molecular targets in Hodgkin and Reed-Sternberg cells"],"prefix":"10.3389","volume":"14","author":[{"given":"Hummaira","family":"Sadaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Ambroziak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Binkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakkapong","family":"Kluebsoongnoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Steciuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiusz","family":"Markowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elzbieta","family":"Sarnowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz Jacek","family":"Sarnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryszard","family":"Konopinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"B1","volume-title":"Reed sternberg cells","author":"Aggarwal","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4161\/cib.28602","article-title":"On the origin of giant cells in Hodgkin lymphoma","volume":"7","author":"Rengstl","year":"2014","journal-title":"Commun Integr Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPW3UN9DYLDSPB","article-title":"Flow cytometry can diagnose classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity","volume":"131","author":"Fromm","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/756353","article-title":"Role of immune escape mechanisms in hodgkin\u2019s lymphoma development and progression: a whole new world with therapeutic implications","volume":"2012","author":"de la Cruz-Merino","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.618","article-title":"Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and reed-stenberg cells of Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1182\/blood.2021013881","article-title":"Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies","volume":"139","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3303","article-title":"Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial","volume":"27","author":"Voltin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for hodgkin\u2019s disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/JMR.605","article-title":"Human CD30: structural implications from epitope mapping and modeling studies","volume":"16","author":"Dong","year":"2003","journal-title":"J Mol Recognition"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0045244","article-title":"Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-\u03baB signaling","volume":"7","author":"Buchan","year":"2012","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0888-7543(05)80203-4","article-title":"Assignment of the human CD30 (Ki-1) gene to 1p36","volume":"14","author":"Fonatsch","year":"1992","journal-title":"Genomics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.8.3229","article-title":"CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors","volume":"157","author":"Agrawal","year":"1996","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16624","article-title":"Identification of Hodgkin and reed-sternberg cell-specific genes by gene expression profiling","volume":"111","author":"K\u00fcppers","year":"2003","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-1012\/174150\/AM\/ELEVATED-SERUM-LEVELS-OF-SCD30-AND-IL-6-AND","article-title":"Elevated serum levels of sCD30 and IL6 and detectable il10 precede classical hodgkin lymphoma diagnosis","volume":"26","author":"Levin","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2020.615141\/BIBTEX","article-title":"Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily","volume":"8","author":"Kucka","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1091\/MBC.E14-08-1290\/ASSET\/IMAGES\/LARGE\/MBC-26-993-G005.JPEG","article-title":"TRAF2 recruitment via T61 in CD30 drives NF\u03baB activation and enhances hESC survival and proliferation","volume":"26","author":"Thakar","year":"2015","journal-title":"Mol Biol Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.17.3.1535","article-title":"Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2","volume":"17","author":"Duckett","year":"1997","journal-title":"Mol Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.JMII.2015.05.017","article-title":"Roles of bcl-2 and caspase-9 and -3 in CD30-induced human eosinophil apoptosis","volume":"50","author":"Lee","year":"2017","journal-title":"J Microbiology Immunol Infection"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.5105","article-title":"CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis","volume":"165","author":"Muta","year":"2000","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/S40164-020-00197-9","article-title":"AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL","volume":"10","author":"Wu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101484","article-title":"Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice","volume":"208","author":"Gaspal","year":"2011","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000523823","article-title":"Hodgkin Lymphoma on hemodialysis successfully treated with extended courses of brentuximab vedotin","volume":"15","author":"Uchimura","year":"2022","journal-title":"Case Rep Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1499723","article-title":"Efficacy of antibody\u2013drug conjugate brentuximab vedotin in treating hodgkin\u2019s lymphoma","volume":"18","author":"Viviani","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204870","article-title":"Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma","volume":"13","author":"Hollander","year":"2018","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09028-4","article-title":"High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed\/Refractory classical Hodgkin lymphoma","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hon.2437\\_54","article-title":"Blockade of the pd-1 checkpoint with anti\u2013Pd-L1 antibody avelumab is sufficient for clinical activity in Relapsed\/Refractory classical Hodgkin lymphoma (CHL)","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for reed-sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1381","article-title":"Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2","volume":"99","author":"Joos","year":"2002","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large b-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5399","article-title":"The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines","volume":"37","author":"Doi","year":"2017","journal-title":"Oncol Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large b-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large b-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2010.08.019","article-title":"Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV","volume":"305","author":"Taylor","year":"2011","journal-title":"Cancer Lett"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-\u03baB","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119849","article-title":"Constitutive nuclear factor-\u03bab-RelA activation is required for proliferation and survival of hodgkin\u2019s disease tumor cells","volume":"100","author":"Bargou","year":"1997","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-\u03baB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2018.03.012","article-title":"High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in Hodgkin lymphoma","volume":"11","author":"Guo","year":"2018","journal-title":"Transl Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","article-title":"PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer","volume":"11","author":"Yu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13215487\/S1","article-title":"Cd8+ t lymphocytes immune depletion and lag-3 overexpression in hodgkin lymphoma tumor microenvironment exposed to anti-pd-1 immunotherapy","volume":"13","author":"Michot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2019-130794","article-title":"May tigit (T cell ig and ITIM domain) expression be a new target for Hodgkin lymphoma","volume":"134","author":"Annibali","year":"2019","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2021-151728","article-title":"Safety and efficacy of vibostolimab and pembrolizumab in patients with relapsed or refractory hematologic malignancies: a multicohort, open-label, phase 2 study","volume":"138","author":"Yusuf","year":"2021","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/BJH.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3463","article-title":"Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape","volume":"38","author":"Liu","year":"2020","journal-title":"Cell Biochem Funct"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.874645","article-title":"The status and prospects of epigenetics in the treatment of lymphoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3765","article-title":"Epigenetic processes play a major role in b-cell-specific gene silencing in classical Hodgkin lymphoma","volume":"107","author":"Ushmorov","year":"2006","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-256446","article-title":"KLF4 is a tumor suppressor in b-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma","volume":"116","author":"Guan","year":"2010","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.061770","article-title":"Ets1 encoding a transcription factor involved in b-cell differentiation is recurrently deleted and down-regulated in classical hodgkin\u2019s lymphoma","volume":"97","author":"Overbeck","year":"2012","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431429","article-title":"PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells","volume":"121","author":"Yuki","year":"2013","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.280","article-title":"Role of early b-cell factor 1 (EBF1) in Hodgkin lymphoma","volume":"27","author":"Bohle","year":"2013","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1267\/ahc.14012","article-title":"BOB.1-positive classical hodgkin\u2019s lymphoma carries hypermethylation of its promoter as epigenetic marker of gene-silencing memory","volume":"47","author":"Watanabe","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.194","article-title":"Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of b cell-specific genes","volume":"26","author":"Ammerpohl","year":"2012","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/ng1990","article-title":"Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome","volume":"39","author":"Weber","year":"2007","journal-title":"Nat Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/path.2242","article-title":"Selective loss of b-cell phenotype in lymphocyte predominant Hodgkin lymphoma","volume":"213","author":"Tedoldi","year":"2007","journal-title":"J Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical hodgkin\u2019s lymphoma and primary mediastinal large b-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3827","article-title":"Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: a rationale for combination with small molecular weight inhibitors","volume":"50","author":"Swerev","year":"2017","journal-title":"Int J Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08438.x","article-title":"Response to 5-azacytidine in a patient with relapsed Hodgkin lymphoma and a therapy-related myelodysplastic syndrome","volume":"154","author":"D\u2019Al\u00f2","year":"2011","journal-title":"Br J Haematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-016-0363-1","article-title":"High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy","volume":"9","author":"Falchi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-9822(06)00296-x","article-title":"Acetylation of general transcription factors by histone acetyltransferases","volume":"7","author":"Imhof","year":"1997","journal-title":"Curr Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031138","article-title":"Classical hodgkin\u2019s lymphoma shows epigenetic features of abortive plasma cell differentiation","volume":"96","author":"Seitz","year":"2011","journal-title":"Haematologica"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.21.3409","article-title":"Effects of histone deacetylase inhibitors on HIF-1","volume":"5","author":"Liang","year":"2006","journal-title":"Cell Cycle"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1517\/14728221003796609","article-title":"Class i histone deacetylases 1, 2 and 3 are highly expressed in classical hodgkin\u2019s lymphoma","volume":"14","author":"Adams","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000610","article-title":"Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma","volume":"29","author":"Huang","year":"2018","journal-title":"Anticancer Drugs"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors","volume":"147","author":"Gloghini","year":"2009","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1215","article-title":"Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory Hodgkin lymphoma","volume":"26","author":"Janku","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.608448","article-title":"A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: southwest oncology group study S0517","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142406","article-title":"ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory hodgkin lymphoma","volume":"101","author":"Batlevi","year":"2016","journal-title":"Haematologica"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070294","article-title":"Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling","volume":"172","author":"Akimzhanov","year":"2008","journal-title":"Am J Pathol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1197","article-title":"Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression","volume":"104","author":"Ushmorov","year":"2004","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.579","article-title":"The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in hodgkin\u2019s lymphoma","volume":"30","author":"Anderton","year":"2011","journal-title":"Oncogene"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11020","article-title":"Strong KDM4B and KDM4D expression associates with radioresistance and aggressive phenotype in classical Hodgkin lymphoma","volume":"36","author":"Bur","year":"2016","journal-title":"Anticancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1009902","article-title":"Evidence that Swi\/Snf directly represses transcription in s. cerevisiae","volume":"16","author":"Martens","year":"2002","journal-title":"Genes Dev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.8.2254","article-title":"Continuous and widespread roles for the swi-snf complex in transcription","volume":"18","author":"Biggar","year":"1999","journal-title":"EMBO J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0221-1","article-title":"A non-canonical SWI\/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation","volume":"20","author":"Michel","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cell.2013.02.036","article-title":"Reversible disruption of mSWI\/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma","volume":"153","author":"Kadoch","year":"2013","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin reed-sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-015-0242-8","article-title":"DNA Methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas","volume":"38","author":"Dhiab","year":"2015","journal-title":"Cell Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large b-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306672200","article-title":"Ki-1\/57 interacts with RACK1 and is a substrate for the phosphorylation by phorbol 12-myristate 13-acetate-activated protein kinase c","volume":"279","author":"Nery","year":"2004","journal-title":"J Biol Chem"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.22.17.6070-6078.2002","article-title":"The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans","volume":"22","author":"Levine","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2285","article-title":"esBAF facilitates pluripotency by conditioning the genome for LIF\/STAT3 signalling and by regulating polycomb function","volume":"13","author":"Ho","year":"2011","journal-title":"Nat Cell Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.043","article-title":"Control of developmental regulators by polycomb in human embryonic stem cells","volume":"125","author":"Lee","year":"2006","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64583-X","article-title":"Coexpression of BMI-1 and EZH2 polycomb group genes in reed-sternberg cells of hodgkin\u2019s disease","volume":"157","author":"Raaphorst","year":"2000","journal-title":"Am J Pathol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800577","article-title":"Variability in the expression of polycomb proteins in different normal and tumoral tissues. a pilot study using tissue microarrays","volume":"19","author":"S\u00e1nchez-Beato","year":"2006","journal-title":"Modern Pathol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63175-6","article-title":"Unique polycomb gene expression pattern in hodgkin\u2019s lymphoma and hodgkin\u2019s lymphoma-derived cell lines","volume":"164","author":"Dukers","year":"2004","journal-title":"Am J Pathol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1499407","article-title":"pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene","volume":"21","author":"Kotake","year":"2007","journal-title":"Genes Dev"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.46.3.211","article-title":"Expression of c-myc and bcl-2 oncogene products in reed-sternberg cells independent of presence of Epstein-Barr virus","volume":"46","author":"Jiwa","year":"1993","journal-title":"J Clin Pathol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.203","article-title":"An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma","volume":"32","author":"Lollies","year":"2018","journal-title":"Leukemia"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.12.3404","article-title":"RYBP, a new repressor protein that interacts with components of the mammalian polycomb complex, and with the transcription factor YY1","volume":"18","author":"Garc\u00eda","year":"1999","journal-title":"EMBO J"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/path.1661","article-title":"Abnormal PcG protein expression in hodgkin\u2019s lymphoma. relation with E2F6 and NF\u03baB transcription factors","volume":"204","author":"S\u00e1nchez-Beato","year":"2004","journal-title":"J Pathol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi111","article-title":"Deregulated expression of polycomb-group oncogenes in human malignant lymphomas and epithelial tumors","volume":"14","author":"Raaphorst","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001180","article-title":"Utility of combined EZH2, p-ERK1\/2, p-STAT, and MYC expression in the differential diagnosis of EZH2-positive Hodgkin lymphomas and related Large b-cell lymphomas","volume":"43","author":"Tian","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-020-00937-8\/TABLES\/2","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/D41573-020-00024-0","article-title":"FDA Approves an inhibitor of a novel \u201cepigenetic writer","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet Haematol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10015","article-title":"PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma","volume":"7","author":"Cordeiro","year":"2016","journal-title":"Oncotarget"},{"key":"B133","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/hdy.2010.53","article-title":"Transposable elements in the mammalian germline: a comfortable niche or a deadly trap","volume":"105","author":"Zamudio","year":"2010","journal-title":"Heredity (Edinb)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090267","article-title":"Piwi is required in multiple cell types to control germline stem cell lineage development in the drosophila ovary","volume":"9","author":"Ma","year":"2014","journal-title":"PloS One"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0808830105","article-title":"MicroRNA-directed transcriptional gene silencing in mammalian cells","volume":"105","author":"Kim","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: biogenesis, function and role in cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr Genomics"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096784","article-title":"MicroRNA expression profiling in classic Hodgkin lymphoma","volume":"111","author":"Navarro","year":"2008","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08980","article-title":"Hodgkin Lymphoma cell lines are characterized by a specific miRNA expression profile","volume":"11","author":"Gibcus","year":"2009","journal-title":"Neoplasia"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07909.x","article-title":"Comparison of miRNA profiles of microdissected Hodgkin\/Reed-sternberg cells and Hodgkin cell lines versus CD77 + b-cells reveals a distinct subset of differentially expressed miRNAs","volume":"147","author":"Van Vlierberghe","year":"2009","journal-title":"Br J Haematol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.02.016","article-title":"miR-24-3p is overexpressed in Hodgkin lymphoma and protects Hodgkin and reed-sternberg cells from apoptosis","volume":"187","author":"Yuan","year":"2017","journal-title":"Am J Pathol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s13353-021-00614-7","article-title":"MicroRNA signature in classical Hodgkin lymphoma","volume":"62","author":"Paczkowska","year":"2021","journal-title":"J Appl Genet"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102292","article-title":"The tumor suppressive mir-148a is epigenetically inactivated in classical Hodgkin lymphoma","volume":"9","author":"Paczkowska","year":"2020","journal-title":"Cells"},{"key":"B144","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12864-015-1881-x","article-title":"Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells","volume":"16","author":"Ma","year":"2015","journal-title":"BMC Genomics"},{"key":"B145","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10020-018-0050-5","article-title":"The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9","volume":"24","author":"Xu","year":"2018","journal-title":"Mol Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.28584","article-title":"MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK\/MAPK pathway","volume":"15","author":"Wu","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2020_6017","article-title":"MALAT-1 regulates the AML progression by promoting the m6A modification of ZEB1","volume":"70","author":"Jin","year":"2023","journal-title":"Acta Biochim Pol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156670","article-title":"The long non-coding RNA MALAT1 is necessary for hematopoietic stem and progenitor cell expansion and preleukemic myeloproliferation in TET2 deficient myeloid neoplasms","volume":"140","author":"Ben-Crentsil","year":"2022","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/srep02535","article-title":"MicroRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus","volume":"3","author":"Leucci","year":"2013","journal-title":"Sci Rep"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.05.011","article-title":"Long noncoding RNA expression profiling in normal b-cell subsets and Hodgkin lymphoma reveals Hodgkin and reed-sternberg cell\u2013specific long noncoding RNAs","volume":"186","author":"Tayari","year":"2016","journal-title":"Am J Pathol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2015.08.044","article-title":"Structural and functional diversity of topologically associating domains","volume":"589","author":"Dekker","year":"2015","journal-title":"FEBS Lett"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw1668","article-title":"Principles of genome folding into topologically associating domains","volume":"5","author":"Szabo","year":"2019","journal-title":"Sci Adv"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/s41467-017-00320-1","article-title":"Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility","volume":"8","author":"Sud","year":"2017","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2012.01.025","article-title":"HDAC modulation and cell death in the clinic","volume":"318","author":"Dell\u2019Aversana","year":"2012","journal-title":"Exp Cell Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.05.004","article-title":"Epigenetic mechanisms of importance for drug treatment","volume":"35","author":"Ivanov","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.1021678","article-title":"Advancements in the delivery of epigenetic drugs","volume":"12","author":"Cramer","year":"2015","journal-title":"Expert Opin Drug Delivery"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1155468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T10:29:52Z","timestamp":1684319392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1155468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":159,"alternative-id":["10.3389\/fimmu.2023.1155468"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1155468","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"1155468"}}